PFE
PFE
equity
N/A
Accuracy
Recent Predictions
Incorrect: 0
Pending: 23
Prediction
Author
Predicted at
Status
Video
Pfizer faces a risk of losing $15 billion in annual revenue by 2028 due to patent expirations on key drugs (Ebrance, Excandi, Eloquis).
"$15 billion in annual revenue is at risk by 2028 from expiring exclusivity on major drugs like Ebran..."
Jul 30, 2025
Pending
Pfizer's promising late-stage lung and bladder cancer drug candidates are predicted to potentially reshape standard of care by 2026 and beyond.
"While promising lateage candidates in lung and bladder cancer could reshape standard of care by 2026..."
Jul 25, 2025
Pending
Pfizer (PFE) expects revenues to be heavily weighted towards Q4 2024, with a high level of cash collections potentially carrying over into Q1 2025 due to seasonal business nature.
"we expect heavily waiting of revenues to the fourth quarter as our businesses become more seasonal n..."
Jul 30, 2024
Pending
Pfizer (PFE) plans to initiate a Phase 3 program for its Cat-6 medicine within the next six months.
"plan to initiate a phase three program over the next six months"
Jul 30, 2024
Pending
Pfizer (PFE) expects to be the second company after Eli Lilly (LLY) to bring an oral GLP-1 (Danuglipron) to market if it progresses through registration studies.
"we should be the second after Lily if Danel progress into registration enabling St"
Jul 30, 2024
Pending
Pfizer (PFE) believes the annual peak sales potential for its RSV vaccine (Abrysvo) is now 'more promising' than the previously stated $2 billion due to strong emphasis from the medical community.
"what I would say if everything if anything uh things have become more promising since the time that ..."
Jul 30, 2024
Pending
Pfizer (PFE) does not expect the market for its Vyndaqel/Vyndamax products to remain as large once generic competitors enter.
"we do not expect that uh the market will continue being as big particularly for us after we see gene..."
Jul 30, 2024
Pending
Pfizer (PFE) expects future margin expansion.
"fiser beat and raised and talked up future margin expansion"
Jul 30, 2024
Pending
Pfizer (PFE) is raising its full-year 2024 guidance ranges for revenue and adjusted diluted earnings per share.
"we are raising our full year 24 guidance ranges for revenue and adjusted diluted earnings percent"
Jul 30, 2024
Pending
Pfizer (PFE) aims to achieve its 2030 oncology strategy goals of delivering at least eight blockbuster medicines and doubling the number of patients treated with its innovative cancer medicines.
"We will continue working toward our 2030 oncology strategy goals on delivering eight or more Blockbu..."
Jul 30, 2024
Pending
Pfizer (PFE) expects to see the impact of securing preferred coverage for Viaty with a large national payer in 2025.
"We expect to see the impact of this in 2025."
Jul 30, 2024
Pending
The first phase of Pfizer's (PFE) manufacturing optimization program is expected to deliver approximately $1.5 billion in savings by the end of 2027, with some savings anticipated to be realized starting in 2025.
"the first phase is expected to deliver approximately $1.5 billion in savings by the end of 2027 some..."
Jul 30, 2024
Pending
Pfizer (PFE) expects to record an approximately $400 million charge in Q3 2024 related to a facility sale.
"Additionally we expect to record a charge of approximately $400 million in the third quarter of 24"
Jul 30, 2024
Pending
Pfizer (PFE) expects to resume the monetization of its 23% Viatris stake in the future.
"we expect to resume monetization of our 23% Halon stake in the future"
Jul 30, 2024
Pending
Pfizer (PFE) updated its full-year 2024 guidance: revenue to $59.5-$62.5 billion, operational revenue growth (ex-COVID) to 9-11%, COVID product revenue to $8.5 billion (Comirnaty $5 billion, Paxlovid $3.5 billion), adjusted tax rate to ~13%, and adjusted diluted EPS to $2.45-$2.65.
"we are raising our fouryear Revenue range by $1 billion and our adjusted diluted earnings per share ..."
Jul 30, 2024
Pending
Pfizer (PFE) is on track to achieve at least $4 billion in net savings from its cost realignment program by the end of 2024.
"we remain on track to deliver at least $4 billion of net savings from our cost realignment program b..."
Jul 30, 2024
Pending
Pfizer (PFE) expects gross margin rates to improve to the mid-70s and operating margins to return to pre-pandemic levels in the near future due to ongoing investments and cost programs.
"it would imply that margin gross margin rates would actually improve uh versus the low 70s ... to pr..."
Jul 30, 2024
Pending
Pfizer (PFE) expects its RSV vaccine (Abrysvo) to be well-positioned for the upcoming fall season in the US, with strengthened contracts taking effect in August 2024.
"for uh a briso I think we are very well positioned going into the fall season in the US for three ma..."
Jul 30, 2024
Pending
Pfizer (PFE) is predicted to potentially reach $33-36, with a 'real gap fill' around $39, provided it holds current levels.
"I think fizer can go to 33 to 36 even 39 but it you know there's nothing to talk about until it real..."
Jul 18, 2024
Pending
Pfizer stock is predicted to reach $33-$39 if it holds its current level for a few days.
"I think fizer can go to 33 to 36 even 39 but it you know there's nothing to talk about until it real..."
Jul 18, 2024
Pending
If Pfizer (PFE) stock price breaks above $30, it is predicted to easily reach $33-$37.
"if fiser breaks through 30... I think the stock could go to 33 to 37 which is still which is pretty ..."
Jul 16, 2024
Pending
Pfizer (PFE) stock is predicted to reach $33-$37 (10-20% higher than $30) if it breaks above $30 and delivers a strong earnings report.
"if fiser breaks through 30 I think it's a new ball game... I think the stock could go to 33 to 37 wh..."
Jul 16, 2024
Pending
The speaker prefers to buy Pfizer stock at a lower price point, potentially after its next earnings report if the stock drops, to capitalize on its 6% dividend yield.
"I prefer fizer at the lower end if if Again by next earnings if it drops that'll probably be our div..."
Jul 8, 2024
Pending